Atlantic Union Bankshares Corp Grows Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Atlantic Union Bankshares Corp lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,510 shares of the pharmaceutical company’s stock after purchasing an additional 385 shares during the period. Atlantic Union Bankshares Corp’s holdings in Vertex Pharmaceuticals were worth $2,303,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of VRTX. Connor Clark & Lunn Investment Management Ltd. raised its stake in Vertex Pharmaceuticals by 30.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 5,097 shares of the pharmaceutical company’s stock worth $1,772,000 after acquiring an additional 1,197 shares in the last quarter. O Shaughnessy Asset Management LLC increased its stake in Vertex Pharmaceuticals by 32.3% in the third quarter. O Shaughnessy Asset Management LLC now owns 13,308 shares of the pharmaceutical company’s stock valued at $4,628,000 after purchasing an additional 3,246 shares during the period. Mather Group LLC. increased its stake in Vertex Pharmaceuticals by 13.3% in the third quarter. Mather Group LLC. now owns 3,592 shares of the pharmaceutical company’s stock valued at $1,249,000 after purchasing an additional 422 shares during the period. Trexquant Investment LP acquired a new position in Vertex Pharmaceuticals in the third quarter valued at $528,000. Finally, Tower Research Capital LLC TRC increased its stake in Vertex Pharmaceuticals by 59.2% in the third quarter. Tower Research Capital LLC TRC now owns 15,406 shares of the pharmaceutical company’s stock valued at $5,357,000 after purchasing an additional 5,727 shares during the period. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 2,350 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $439.11, for a total transaction of $1,031,908.50. Following the sale, the executive vice president now directly owns 53,523 shares of the company’s stock, valued at $23,502,484.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 2,350 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $439.11, for a total transaction of $1,031,908.50. Following the sale, the executive vice president now directly owns 53,523 shares of the company’s stock, valued at $23,502,484.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $478.00, for a total transaction of $1,089,840.00. Following the sale, the chief marketing officer now directly owns 32,379 shares in the company, valued at $15,477,162. The disclosure for this sale can be found here. Insiders have sold 28,366 shares of company stock worth $13,058,787 in the last ninety days. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Trading Down 0.8 %

NASDAQ VRTX opened at $468.72 on Friday. Vertex Pharmaceuticals Incorporated has a 12 month low of $335.82 and a 12 month high of $486.42. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. The company has a market capitalization of $120.95 billion, a price-to-earnings ratio of 30.42, a price-to-earnings-growth ratio of 2.43 and a beta of 0.41. The company’s fifty day moving average price is $444.89 and its two-hundred day moving average price is $426.17.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The firm had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.58 billion. During the same period in the prior year, the firm posted $2.67 EPS. The firm’s revenue was up 13.3% compared to the same quarter last year. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Argus lifted their price objective on shares of Vertex Pharmaceuticals from $465.00 to $550.00 and gave the company a “buy” rating in a research note on Monday, June 17th. Guggenheim lifted their price objective on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 24th. Canaccord Genuity Group reaffirmed a “sell” rating and issued a $371.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Finally, Redburn Atlantic began coverage on shares of Vertex Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $545.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $448.61.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.